Paloma Encinas

Paloma Encinas

Auto-generated profile, based on publicly available information

Paloma Encinas

Department of Biotechnology National Institute of Agricultural and Food Research and Technology (INIA‐CSIC) Madrid Spain

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2015 in Applied Microbiology and Biotechnology
Verified
Journal Article
Closed access
PDF file
BCBlanca Chinchilla
Blanca Chinchilla
PEPaloma Encinas
Paloma Encinas
AEAmparo Estepa
Amparo Estepa
JMJulio Morales
Julio Morales
Eduardo Gomez-CasadoEduardo Gomez-Casado
Eduardo Gomez-Casado

17 August 2023 in Transboundary and Emerging Diseases
Verified
Journal Article
Open access
PDF file
PEPaloma Encinas
Paloma Encinas
AEAlba Escalera
Alba Escalera
TATeresa Aydillo
Teresa Aydillo
IMIrene Iglesias Martin
Irene Iglesias Martin
MNMartha I. Nelson
Martha I. Nelson
GRGustavo del Real
Gustavo del Real
Effective control of zoonotic infectious diseases requires identifying the animal species involved in the infectious cycle as transmitters or reservoirs where the pathogen could persist and evolve, increasing the risk of reintroduction of new variants in humans and animals. Multiple surveillance studies have detected the presence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) or specific antibodies in free-ranging white-tailed deer (Odocoileus virginianus) in North America, being the wild mammal species with the most reported cases of SARS-CoV-2 infection. However, so far, all attempts to detect the infection in European cervids have been unsuccessful. In this study, we demonstrated the presence of specific antibodies against SARS-CoV-2 in European fallow deer (Dama dama) and red deer (Cervus elaphus) in Spain. However, all samples of European roe deer (Capreolus capreolus), taxonomically related to the American white-tailed deer, were seronegative for the virus. We tested 215 serum samples from roe deer (n116), red deer (n63), and fallow deer (n36) collected in eight provinces of central-southern Spain between 2017 and 2022. We first screened sera by a surrogate virus neutralization test (sVNT) ELISA based on the binding of the receptor-binding domain of SARS-CoV-2 to the angiotensin-converting enzyme 2 (ACE2) receptor and then confirmed positive samples by a conventional virus neutralization test (cVNT) against the Alpha, Delta, and Omicron variants. Four fallow deer and two red deer samples were seropositive in both neutralization assays. Four samples of fallow deer and one of red deer, collected in a suburban park near Madrid in February 2022, had antibodies against the Alpha, Delta, and Omicron variants, while a seropositive sample of red deer, collected in a rural area in February 2021, was specific for the Delta variant. All samples collected before the start of the pandemic in Spain were seronegative for sVNT, which also indicates that there are not cross-reactive antibodies potentially elicited by other viruses antigenically related to SARS-CoV-2. The results indicate probable human-to-deer transmission of SARS-CoV-2, but do not clarify whether there was subsequent spread within herds.

27 February 2013 in Zebrafish
Verified
Journal Article
Closed access
BCBlanca Chinchilla
Blanca Chinchilla
Eduardo Gomez-CasadoEduardo Gomez-Casado
Eduardo Gomez-Casado
PEPaloma Encinas
Paloma Encinas
Alberto FalcóAlberto Falcó
Alberto Falcó
AEAmparo Estepa
Amparo Estepa
JMJulio Morales
Julio Morales
We studied humoral long-term adaptive viral neutralization responses in zebrafish ( Danio rerio ), an increasingly useful vertebrate model for viral diseases actually limited by the absence of standardized anti-zebrafish immunoglobulin M (IgM) antibodies. We established an alternative method, similar to those used in other fish, to achieve a first estimation of zebrafish anti-viral antibody-like responses. We used the viral hemorrhagic septicemia virus (VHSV) model because, although protection after this non-natural infection was demonstrated in cold-acclimatized zebrafish, little is known about their induced anti-VHSV antibody-like responses. Therefore, we first optimized a micro-neutralization method based on immunostaining VHSV-infected fish cell monolayers to detect zebrafish neutralizing activity in plasma samples in one day. We then used the method to measure the specific anti-VHSV neutralization in plasma obtained from individual zebrafish under various VHSV challenges or immunization protocols. The neutralizing activity was inhibited by protein A-sepharose and rabbit anti-zebrafish IgM antibodies, suggesting the implication of IgM zebrafish antibodies in such responses. To our knowledge, this is the first report to demonstrate detectable and significant VHSV neutralization titers in zebrafish surviving VHSV infections. This micro-method might be useful, not only for the follow-up of infection/vaccine development in the zebrafish/VHSV model in particular, but also for similar work involving other in vitro neutralizable zebrafish pathogens. This technique might also further the development of alternative ELISA assay methods to measure specific immunoglobulins in zebrafish.

10 February 2026 in Zoonoses and Public Health
Verified
Journal Article
Open access
PEPaloma Encinas
Paloma Encinas
ANAitor Nogales
Aitor Nogales
EEEstela Escribano‐Romero
Estela Escribano‐Romero
MBM. Ángeles Martín del Burgo
M. Ángeles Martín del Burgo
JLJorge Ramón López‐Olvera
Jorge Ramón López‐Olvera
GRGustavo del Real
Gustavo del Real
Introduction: Influenza A viruses (IAVs) are responsible for respiratory infections in a wide range of species, including birds, swine and humans. The role of wild boar ( Sus scrofa ) in IAV epidemiology remains underexplored. Here, we present a longitudinal serologic and virologic surveillance study of wild boars in Spain from 2015 to 2023. Methods: A total of 1643 nasal exudates and 2932 serum samples were analysed using quantitative RT‐PCR, ELISA and haemagglutination inhibition (HI) assays to detect IAV positive samples and IAV targeted antibodies to characterise circulating viral subtypes. In addition, in the context of highly pathogenic avian influenza H5N1 outbreaks, we explored the potential transmission of avian IAV to wild boar. Results: In summary, 6% of the serum samples tested positive and one IAV H3N1 was isolated. The seroprevalence remained stable from 2015 to 2018, undetected in 2019 and increased significantly from 2020 to 2023. The most frequently detected subtype was Eurasian avian‐like H1 (clade 1C) while pandemic H1 (clade 1A) and human‐like H1 (clade 1B) were less common. Human seasonal‐like H3 strains from the 2000s (2000s‐like H3) emerged in 2017 and have become more seroprevalent in recent years. A subset of wild boar sera from areas overlapping with H5N1 HPAI outbreaks in poultry and wild birds tested positive for recombinant H5 by ELISA, although H5N1 HI assays were negative. Conclusions: The monitoring of IAV in wild boar population allowed the identification of the temporal and spatial trends and shifts in the prevalence and characterisation of the infecting IAV strains. Our data suggest potential spillover events from human or other sources and support the inclusion of integrated monitoring of the wild suids as IAV reassortment‐prone hosts in influenza surveillance programs.

22 December 2025 in Influenza and Other Respiratory Viruses
Verified
Journal Article
Open access
PEPaloma Encinas
Paloma Encinas
ALAntonio Lalueza‐Blanco
Antonio Lalueza‐Blanco
AGAna Isabel García‐Vaquero
Ana Isabel García‐Vaquero
MNMartha I. Nelson
Martha I. Nelson
AGAdolfo García‐Sastre
Adolfo García‐Sastre
GRGustavo del Real
Gustavo del Real
Swine influenza A viruses (SIVs) pose a zoonotic risk, with variants detected in humans in Europe. This study evaluated the efficacy of the 2021/2022 seasonal influenza vaccine against SIVs. Forty‐six postvaccination human sera were tested via hemagglutination inhibition (HI) assay against Spanish SIV genotypes. Seroprotection rate (SPR, HI titer ≥ 40) was 76% (95% CI: 64–88) and 91% (95% CI: 83–99) for human vaccine strains H1 and H3, respectively. SPRs were 67% (95% CI: 53–81) for pandemic swine H1, 64% (95% CI: 50–78) for human seasonal‐like H1, 17%–46% for Eurasian avian‐like H1, 15% (95% CI: 5–25) for human seasonal‐like H3 from the 1970s, and 83%–93% for human seasonal‐like H3 from the 2000s SIVs.

5 February 2025
Verified
Preprint
Open access
PEPaloma Encinas
Paloma Encinas
ANAitor Nogales
Aitor Nogales
MNMartha Nelson
Martha Nelson
AGAdolfo Garcia-Sastre
Adolfo Garcia-Sastre
GRGustavo del Real
Gustavo del Real
Background Swine influenza causes significant economic losses worldwide, making it one of the top three health challenges affecting the swine industry. In addition, swine influenza viruses can cross species barriers and infect humans, posing serious public health risks. Vaccination is an essential tool for controlling the severity of the disease in swine and its spillover risk to humans. Due to the high antigenic variability of influenza A viruses (IAV) as a result of mutation and genomic reassortment, it is necessary to update vaccine strains to better match and neutralize circulating viruses at a given time and place. In this study we tested the efficacy of current swine influenza vaccines against influenza A viruses circulating in Spain. Methods Sera from mice immunized with swine influenza vaccines are tested against swine influenza A strains circulating in Spain using a hemagglutination inhibition (HI) serological assay. Results Current swine influenza vaccines show variable protective efficacy depending on the type of circulating swine IAV. Protective HI antibody titers (≥1/40) are induced against some field virus isolates of the Eurasian avian-like H1 (EaswH1) and human seasonal-like (huswH1) lineages, while no protection is obtained against other recent virus isolates of these lineages. Similarly, the vaccine does not protect against field virus isolates of recent porcine H3 lineages of human origin. Conclusions The high antigenic variability of circulating swine influenza A viruses circulating in Spain requires updating vaccines to match new viral variants, not only to increase neutralizing antibody titers, but also to include newly emerging strains that have been omitted in current vaccine formulations.